文献速递淋巴瘤

利妥昔单抗、苯达莫司汀联合低剂量阿糖胞苷诱导治疗老年套细胞淋巴瘤:意大利淋巴瘤基金会多中心2期试验

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
PubMed 文献 · Lancet Haematol · 2016-12-05

这项多中心2期试验纳入57例未治老年套细胞淋巴瘤患者,接受RBAC500方案(利妥昔单抗、苯达莫司汀、低剂量阿糖胞苷)最多6周期。91%患者达完全缓解,40%出现相关毒性,未达预设安全界值,但毒性经支持治疗和减量可控。作者认为RBAC500可考虑为治疗选择,需3期试验研究。

要点

  • 57例老年套细胞淋巴瘤患者接受RBAC500方案,91%达完全缓解。
  • 40%患者出现相关毒性,未达预设安全界值,但经支持治疗和减量可控。
  • 作者认为RBAC500可考虑为治疗选择,需3期试验研究。

核心结论

  • RBAC500是老年套细胞淋巴瘤的有效治疗,虽未达预设安全界值,但血液学毒性经适当支持治疗和减量可控。
  • 作者认为因无需维持治疗,RBAC500可考虑为一种选择,并应在3期试验中研究。

研究设计与样本

  • 多中心2期试验,自意大利29个意大利淋巴瘤基金会中心招募未治、组织学确诊的套细胞淋巴瘤患者。
  • 入组条件:年龄>65岁且综合老年评估为fit,或年龄60-65岁且不适合大剂量化疗联合自体干细胞移植、fit或unfit。
  • 所有患者接受RBAC500方案:利妥昔单抗375 mg/m2第1天、苯达莫司汀70 mg/m2第2-3天、阿糖胞苷500 mg/m2第2-4天,均静脉给药,每4周1次,最多6周期。
  • 主要终点为治疗结束时完全缓解比例和毒性(发生任何停止治疗标准或相关毒性事件)。
  • 复合主要终点判定:57例中>28例达完全缓解且<18例报告毒性视为阳性;2012年5月2日至2014年2月25日入组57例,中位年龄71岁(IQR 67-75)。

主要发现

  • 54例(95%)接受至少4周期RBAC500(3例因毒性停药),38例(67%)完成6周期;2例(4%)疾病进展(1例第4周期后、1例第6周期后)。
  • 52例(91%,单侧95%CI下限85%)达治疗结束完全缓解;57例中23例(40%,单侧95%CI上限53%)发生至少一次相关毒性。
  • 最常见3-4级血液学毒性为中性粒细胞减少(304周期中149周期[49%])和血小板减少(158周期[52%])。
  • 大多数治疗相关非血液学不良事件为1-2级,最常见为乏力(14例[25%])、恶心或呕吐(12例[21%])、输注相关反应或肿瘤溶解综合征(12例[21%])。
  • 41例(72%)需减量;研究期间12例死亡,但无治疗相关死亡。

关键数值与推荐

  • RBAC500方案:利妥昔单抗375 mg/m2第1天、苯达莫司汀70 mg/m2第2-3天、阿糖胞苷500 mg/m2第2-4天,均静脉给药,每4周1次,最多6周期。
  • 复合主要终点阳性标准:57例中>28例达完全缓解且<18例报告毒性。
  • 完全缓解52例(91%,单侧95%CI下限85%);相关毒性23例(40%,单侧95%CI上限53%)。

临床怎么用

  • 作者认为RBAC500可考虑为老年套细胞淋巴瘤的一种选择,并应在3期试验中研究。
  • 作者指出血液学毒性经适当支持治疗和减量可控,且无需维持治疗。

局限性

  • 未达预设安全界值,血液学毒性发生率为40%(单侧95%CI上限53%)。
  • 作者指出需在3期试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination of rituximab, bendamustine, and cytarabine (R-BAC) was highly active in a pilot trial of mantle cell lymphoma, but its use was restricted by high haematological toxicity. We aimed to assess the efficacy and safety of an R-BAC regimen with low-dose cytarabine (RBAC500). METHODS: In this multicentre, phase 2 trial, we recruited previously untreated patients with an established histological diagnosis of mantle cell lymphoma from 29 Fondazione Italiana Linfomi centres in Italy. Patients had to be older than 65 years and fit according to the comprehensive geriatric assessment, or aged 60-65 years if they were ineligible for high-dose chemotherapy plus autologous stem-cell transplantation and were fit or unfit. All patients received RBAC500 (rituximab 375 mg/m2 on day 1, bendamustine 70 mg/m2 on days 2 and 3, and cytarabine 500 mg/m2 on days 2-4; all administered intravenously) every 4 weeks for up to six cycles. Primary endpoints were the proportion of patients achieving complete response at the end of treatment and toxicity, defined as the occurrence of any of the stop treatment criteria or of any episode of relevant toxicity. All patients who started at least one cycle of RBAC500 were included in the primary and safety analyses. Using efficacy and toxicity as a composite primary endpoint, we considered the final conclusion positive if more than 28 of 57 patients achieve complete response and fewer than 18 of 57 patients report toxicities. This study is registered with EudraCT, number 2011-005739-23, and ClinicalTrials.gov, number NCT01662050, and is completed. FINDINGS: Between May 2, 2012, and Feb 25, 2014, we enrolled 57 patients (median age 71 years, IQR 67-75). 54 (95%) patients received at least four RBAC500 cycles (three discontinued because of toxicity), and 38 (67%) completed six cycles. Two (4%) had disease progression (one after the fourth cycle and one after the sixth cycle). All 52 (91%, lower limit of one-sided 95% CI 85%) remaining patients achieved complete response at the end of treatment. 23 (40%, upper limit of one-sided 95% CI 53%) of 57 patients had at least one episode of relevant toxicity. The most frequent grade 3-4 haematological toxicities were neutropenia (149 [49%] of 304 cycles) and thrombocytopenia (158 [52%]). Most treatment-related non-haematological adverse events were of grade 1-2, with the most frequent ones being fatigue (14 [25%] patients), nausea or vomiting (12 [21%]), and infusion-related reactions or tumour lysis syndrome (12 [21%]). 41 (72%) patients required a dose reduction. 12 patients died during the study, but no deaths were related to treatment. INTERPRETATION: RBAC500 is an effective treatment for elderly patients with mantle cell lymphoma and, despite not meeting our prespecified safety boundary, haematological toxicity was manageable with appropriate supportive care and dose reduction. Since maintenance therapy is not required, RBAC500 could be considered an option and should be studied in phase 3 trials. FUNDING: Fondazione Italiana Linfomi and Mundipharma.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2016. PMID: 27927586. doi:10.1016/S2352-3026(16)30185-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。